Bellevue Group AG lifted its holdings in Stryker Co. (NYSE:SYK) by 24.1% during the first quarter, HoldingsChannel.com reports. The fund owned 113,300 shares of the medical technology company’s stock after buying an additional 22,000 shares during the quarter. Stryker makes up 1.8% of Bellevue Group AG’s holdings, making the stock its 18th largest holding. Bellevue Group AG’s holdings in Stryker were worth $18,232,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. River Wealth Advisors LLC boosted its holdings in Stryker by 1.1% during the first quarter. River Wealth Advisors LLC now owns 29,300 shares of the medical technology company’s stock worth $4,715,000 after buying an additional 309 shares in the last quarter. Mogy Joel R Investment Counsel Inc. boosted its holdings in Stryker by 0.4% during the first quarter. Mogy Joel R Investment Counsel Inc. now owns 86,568 shares of the medical technology company’s stock worth $13,931,000 after buying an additional 325 shares in the last quarter. Advisor Partners LLC boosted its holdings in Stryker by 7.2% during the fourth quarter. Advisor Partners LLC now owns 4,827 shares of the medical technology company’s stock worth $779,000 after buying an additional 326 shares in the last quarter. Putnam FL Investment Management Co. boosted its holdings in Stryker by 0.7% during the fourth quarter. Putnam FL Investment Management Co. now owns 44,867 shares of the medical technology company’s stock worth $6,947,000 after buying an additional 332 shares in the last quarter. Finally, LS Investment Advisors LLC boosted its holdings in Stryker by 3.6% during the fourth quarter. LS Investment Advisors LLC now owns 10,249 shares of the medical technology company’s stock worth $1,587,000 after buying an additional 354 shares in the last quarter. 75.98% of the stock is currently owned by hedge funds and other institutional investors.
Stryker opened at $172.81 on Monday, according to MarketBeat.com. The company has a current ratio of 1.64, a quick ratio of 1.08 and a debt-to-equity ratio of 0.64. The firm has a market cap of $64.58 billion, a price-to-earnings ratio of 26.63, a P/E/G ratio of 2.45 and a beta of 0.70. Stryker Co. has a 52-week low of $134.79 and a 52-week high of $173.47.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 26th. The medical technology company reported $1.68 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.60 by $0.08. The business had revenue of $3.24 billion for the quarter, compared to the consensus estimate of $3.20 billion. Stryker had a net margin of 8.00% and a return on equity of 25.65%. The company’s revenue was up 9.7% compared to the same quarter last year. During the same period last year, the firm posted $1.48 earnings per share. research analysts anticipate that Stryker Co. will post 7.23 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 31st. Stockholders of record on Friday, June 29th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 1.09%. The ex-dividend date is Thursday, June 28th. Stryker’s dividend payout ratio is currently 28.97%.
A number of analysts recently issued reports on SYK shares. ValuEngine raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Guggenheim reissued a “buy” rating on shares of Stryker in a report on Wednesday, January 31st. Piper Jaffray Companies reissued a “buy” rating and set a $170.00 price target on shares of Stryker in a report on Wednesday, January 31st. SunTrust Banks reissued a “buy” rating and set a $179.00 price target (up from $161.00) on shares of Stryker in a report on Friday, January 26th. Finally, Stifel Nicolaus increased their price target on shares of Stryker from $183.00 to $187.00 and gave the stock a “buy” rating in a report on Friday, April 27th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have assigned a buy rating to the stock. Stryker has a consensus rating of “Buy” and an average target price of $170.65.
In other news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 4th. The shares were sold at an average price of $166.42, for a total value of $832,100.00. Following the transaction, the insider now directly owns 101,675 shares of the company’s stock, valued at $16,920,753.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Glenn S. Boehnlein sold 750 shares of the firm’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $160.00, for a total transaction of $120,000.00. Following the completion of the transaction, the chief financial officer now directly owns 3,535 shares in the company, valued at $565,600. The disclosure for this sale can be found here. Over the last three months, insiders sold 134,200 shares of company stock worth $22,151,180. Insiders own 7.40% of the company’s stock.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.